alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### National Institutes of Health

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:*                         National Institute of Allergy and Infectious Diseases Special Emphasis Panel; HHS-NIH-CDC-SBIR PHS 2025-1 Phase I: Software or Web Services to Assess Quality and Reproducibility of Data and Information about Therapeutics and Vaccines (Topic 147).                    

*Date:*                         February 5, 2025.                    

*Time:*                         10:00 a.m. to 3:00 p.m.                    

*Agenda:*                         To review and evaluate contract proposals.                    

*Place:*                         National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Rockville, MD 20892 (Video Assisted Meeting).                    

*Contact Person:*                         Sandip Bhattacharyya, Ph.D., Scientific Review Officer, Scientific Review Program, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, MSC-9823, Rockville, MD 20892,                         *sandip.bhattacharyya@nih.gov.*

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)

Dated: January 6, 2025. 

Lauren A. Fleck, 

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2025-00457 Filed 1-10-25; 8:45 am]

BILLING CODE 4140-01-P
# C_2017022EN.01004602.xml

| 23.1.2017 | EN | Official Journal of the European Union | C 22/46 |
| --- | --- | --- | --- |

23.1.2017

EN

Official Journal of the European Union

C 22/46

---

Action brought on 16 September 2016 — LG Electronics/EUIPO (Dual Edge)

(Case T-804/16)

(2017/C 022/63)

Language of the case: English

Parties

Parties

Applicant: LG Electronics, Inc. (Seoul, Republic of Korea) (represented by: M. Graf, lawyer)

Applicant:

Defendant: European Union Intellectual Property Office (EUIPO)

Defendant:

Details of the proceedings before EUIPO

Details of the proceedings before EUIPO

Trade mark at issue: EU word mark ‘Dual Edge’ – Application for registration No 14 463 178

Trade mark at issue:

Contested decision: Decision of the Second Board of Appeal of EUIPO of 2 September 2016 in Case R 832/2016-2

Contested decision

Form of order sought

Form of order sought

The applicant claims that the Court should:

| — | annul the contested decision; |
| --- | --- |

—

annul the contested decision;

| — | order EUIPO to pay the costs. |
| --- | --- |

—

order EUIPO to pay the costs.

Plea in law

Plea in law

| — | Infringement of Article 7(1)(b) and (c) of Regulation No 207/2009. |
| --- | --- |

—

Infringement of Article 7(1)(b) and (c) of Regulation No 207/2009.

---
Exhibit
31.2


Chief
Financial Officer Certification (Section 302)





CERTIFICATION
OF CHIEF FINANCIAL OFFICER


Pursuant
to Section 302 of the Sarbanes-Oxley Act of 2002





I,
Kenneth Faith, certify that:








(1)I have reviewed
this annual report on Form 10-K of Nuclear Solutions, Inc.





(2)Based on my
knowledge, this annual report does not contain any untrue statement of a
material fact or omit to state a material fact necessary to make the statements
made, in light of the circumstances under which such statements were made, not
misleading with respect to the period covered by this annual
report;





(3)Based on my
knowledge, the financial statements and other financial information included in
this annual report, fairly present in all material respects the financial
condition, results of operations and cash flows of the registrant as of, and
for, the periods presented in this annual report;





(4)The registrant’s
other certifying officers and I are responsible for establishing and maintaining
disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e)
and 15d-15(e)) for the registrant and have:





(a)designed such
disclosure controls and procedures, or caused such disclosure controls and
procedures to be designed under our supervision, to ensure that material
information relating to the registrant, including its consolidated subsidiaries,
is made known to us by others within those entities, particularly during the
period in which this annual report is being prepared;





(b)evaluated the
effectiveness of the registrant’s disclosure controls and procedures and
presented in this report our conclusions about the effectiveness of the
disclosure controls and procedures, as of the end of the period covered by this
report based on such evaluation; and





(c)disclosed in this
report any changes in the registrant’s internal control over financial reporting
that occurred during the registrant’s most recent fiscal quarter (the
registrant’s fourth fiscal quarter in the case of an annual report) that has
materially affected, or is reasonably likely to materially affect, the
registrant’s internal control over financial reporting; and





(5)The registrant’s
other certifying officers and I have disclosed, based on our most recent
evaluation of the internal control over financial reporting, to the registrant’s
auditors and the audit committee of registrant’s board of directors (or persons
performing the equivalent functions):





(a)all significant
deficiencies and material weaknesses in the design or operation of internal
control over financial reporting which are reasonably likely to adversely affect
the registrant’s ability to record, process, summarize and report financial
information ; and





(b)any fraud, whether
or not material, that involves management or other employees who have a
significant role in the registrant’s internal control over financial
reporting.


Date:
      April 15, 2009By:
              /s/ Kenneth
      FaithKenneth
      FaithChief Financial
      Officer
Case 3:03-cv-00572-P Document 48 Filed 09/10/2004 Page 1 of 23
Case 3:03-cv-00572-P Document 48 Filed 09/10/2004 Page 2 of 23
Case 3:03-cv-00572-P Document 48 Filed 09/10/2004 Page 3 of 23
Case 3:03-cv-00572-P Document 48 Filed 09/10/2004 Page 4 of 23
Case 3:03-cv-00572-P Document 48 Filed 09/10/2004 Page 5 of 23
Case 3:03-cv-00572-P Document 48 Filed 09/10/2004 Page 6 of 23
Case 3:03-cv-00572-P Document 48 Filed 09/10/2004 Page 7 of 23
Case 3:03-cv-00572-P Document 48 Filed 09/10/2004 Page 8 of 23
Case 3:03-cv-00572-P Document 48 Filed 09/10/2004 Page 9 of 23
Case 3:03-cv-00572-P Document 48 Filed 09/10/2004 Page 10 of 23
Case 3:03-cv-00572-P Document 48 Filed 09/10/2004 Page 11 of 23
Case 3:03-cv-00572-P Document 48 Filed 09/10/2004 Page 12 of 23
Case 3:03-cv-00572-P Document 48 Filed 09/10/2004 Page 13 of 23
Case 3:03-cv-00572-P Document 48 Filed 09/10/2004 Page 14 of 23
Case 3:03-cv-00572-P Document 48 Filed 09/10/2004 Page 15 of 23
Case 3:03-cv-00572-P Document 48 Filed 09/10/2004 Page 16 of 23
Case 3:03-cv-00572-P Document 48 Filed 09/10/2004 Page 17 of 23
Case 3:03-cv-00572-P Document 48 Filed 09/10/2004 Page 18 of 23
Case 3:03-cv-00572-P Document 48 Filed 09/10/2004 Page 19 of 23
Case 3:03-cv-00572-P Document 48 Filed 09/10/2004 Page 20 of 23
Case 3:03-cv-00572-P Document 48 Filed 09/10/2004 Page 21 of 23
Case 3:03-cv-00572-P Document 48 Filed 09/10/2004 Page 22 of 23
Case 3:03-cv-00572-P Document 48 Filed 09/10/2004 Page 23 of 23
# C_2016410EN.01002902.xml

| 7.11.2016 | EN | Official Journal of the European Union | C 410/29 |
| --- | --- | --- | --- |

7.11.2016

EN

Official Journal of the European Union

C 410/29

---

Action brought on 21 September 2016 — KUKA Systems v EUIPO (MATRIX BODY SHOP)

(Case T-683/16)

(2016/C 410/41)

Language of the case: German

Parties

Parties

Applicant: KUKA Systems GmbH (Augsburg, Germany) (represented by: B. Maneth and C. Huch-Hallwachs, lawyers)

Applicant:

Defendant: European Union Intellectual Property Office (EUIPO)

Defendant:

Details of the proceedings before EUIPO

Details of the proceedings before EUIPO

Trade mark at issue: EU word mark ‘MATRIX BODY SHOP’ — Application No 14 182 661

Trade mark at issue:

Contested decision: Decision of the Fourth Board of Appeal of EUIPO of 19 July 2016 in Case R 2503/2015-4

Contested decision

Form of order sought

Form of order sought

The applicant claims that the Court should:

| — | annul the contested decision; |
| --- | --- |

—

annul the contested decision;

| — | order EUIPO to pay the costs of the proceedings. |
| --- | --- |

—

order EUIPO to pay the costs of the proceedings.

Plea in law

Plea in law

| — | Infringement of Article 7(1)(b) and (c) of Regulation No 207/2009. |
| --- | --- |

—

Infringement of Article 7(1)(b) and (c) of Regulation No 207/2009.

---
IN THE SUPREME COURT OF PENNSYLVANIA

EASTERN DISTRICT

COMMONWEALTH OF PENNSYLVANIA,

Respondent

v.

JASON PEREZ,

Petitioner

:

:

:

:

:

:

:

:

:

:

:

No. 515 EAL 2016

Petition for Allowance of Appeal from 

the Order of the Superior Court

ORDER

PER CURIAM

AND NOW, this 19th day of April, 2017, the Petition for Allowance of Appeal is 

DENIED.
# C_2021110EN.01002801.xml

| 29.3.2021 | EN | Official Journal of the European Union | C 110/28 |
| --- | --- | --- | --- |

29.3.2021

EN

Official Journal of the European Union

C 110/28

---

Judgment of the General Court of 10 February 2021 — Biochange Group v EUIPO — mysuperbrand (medical beauty research)

(Case T-98/20) (1)

(EU trade mark - Invalidity proceedings - EU word mark medical beauty research - Absolute grounds for refusal - Descriptiveness - Article 7(1)(c) of Regulation (EC) No 40/94 (now Article 7(1)(c) of Regulation (EU) 2017/1001) - Lack of distinctive character - Article 7(1)(b) of Regulation No 40/94 (now Article 7(1)(b) of Regulation 2017/1001) - Consideration of the facts - Article 95(1) of Regulation 2017/1001)

(2021/C 110/31)

Language of the case: German

Parties

Applicant: Biochange Group GmbH (Bad Schlema, Germany) (represented by: C. König, lawyer)

Defendant: European Union Intellectual Property Office (represented by: D. Walicka, acting as Agent)

Other party to the proceedings before the Board of Appeal of EUIPO, intervener before the General Court: mysuperbrand GmbH, formerly Laubender GmbH (Vienna, Austria) (represented by: M. Woller, lawyer)

Re:

Action brought against the decision of the Second Board of Appeal of EUIPO of 8 November 2019 (Case R 114/2019-2) relating to invalidity proceedings between Laubender and Biochange Group.

Operative part of the judgment

The Court:

| 1. | Annuls the decision of the Second Board of Appeal of the European Union Intellectual Property Office (EUIPO) of 8 November 2019 (Case R 114/2019-2) as regards ‘baby food’ in Class 5 of the Nice Agreement Concerning the International Classification of Goods and Services for the Purposes of the Registration of Marks of 15 June 1957, as revised and amended; |
| --- | --- |

1.

Annuls the decision of the Second Board of Appeal of the European Union Intellectual Property Office (EUIPO) of 8 November 2019 (Case R 114/2019-2) as regards ‘baby food’ in Class 5 of the Nice Agreement Concerning the International Classification of Goods and Services for the Purposes of the Registration of Marks of 15 June 1957, as revised and amended;

| 2. | Dismisses the action as to the remainder; |
| --- | --- |

2.

Dismisses the action as to the remainder;

| 3. | Orders Biochange Group GmbH, EUIPO and mysuperbrand GmbH each to bear their own costs. |
| --- | --- |

3.

Orders Biochange Group GmbH, EUIPO and mysuperbrand GmbH each to bear their own costs.

---

(1)  OJ C 114, 6.4.2020.

---
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### National Foundation on the Arts and the Humanities

###### Federal Council on the Arts and the Humanities

# AGENCY:

Federal Council on the Arts and the Humanities; National Foundation on the Arts and the Humanities.

# ACTION:

Notice of meeting.

# SUMMARY:

Pursuant to the Federal Advisory Committee Act, notice is hereby given that the Federal Council on the Arts and the Humanities will hold a meeting of the Arts and Artifacts Domestic Indemnity Panel.

# DATES:

The meeting will be held on Wednesday, February 5, 2025, from 12:00 p.m. until adjourned.

# ADDRESSES:

The meeting will be held by videoconference originating at the National Endowment for the Arts, Washington, DC 20506.

# FOR FURTHER INFORMATION CONTACT:

                        Elizabeth Voyatzis, Committee Management Officer, 400 7th Street SW, Room 4060, Washington, DC 20506, (202) 606-8322;                         *evoyatzis@neh.gov.*

# SUPPLEMENTARY INFORMATION:

The purpose of the meeting is for panel review, discussion, evaluation, and recommendation on applications for Certificates of Indemnity submitted to the Federal Council on the Arts and the Humanities, for exhibitions beginning on or after April 1, 2025. Because the meeting will consider proprietary financial and commercial data provided in confidence by indemnity applicants, and material that is likely to disclose trade secrets or other privileged or confidential information, and because it is important to keep the values of objects to be indemnified and the methods of transportation and security measures confidential, I have determined that that the meeting will be closed to the public pursuant to subsection (c)(4) of section 552b of Title 5, United States Code. I have made this determination under the authority granted me by the Chairman's Delegation of Authority to Close Advisory Committee Meetings, dated April 15, 2016.

Dated: January 3, 2025.

Jessica Graves,

Paralegal Specialist, National Endowment for the Humanities.

[FR Doc. 2025-00239 Filed 1-7-25; 8:45 am]

BILLING CODE 7536-01-P
Case 3:04-cv-01271-B Document 92 Filed 11/17/05 Page 1 of 17 PageID 520
 

 Case 3:04-cv-01271-B Document 92 Filed 11/17/05 Page 2 of 17 PageID 521
 

 Case 3:04-cv-01271-B Document 92 Filed 11/17/05 Page 3 of 17 PageID 522
 

 Case 3:04-cv-01271-B Document 92 Filed 11/17/05 Page 4 of 17 PageID 523
 

 Case 3:04-cv-01271-B Document 92 Filed 11/17/05 Page 5 of 17 PageID 524
 

 Case 3:04-cv-01271-B Document 92 Filed 11/17/05 Page 6 of 17 PageID 525
 

 Case 3:04-cv-01271-B Document 92 Filed 11/17/05 Page 7 of 17 PageID 526
 

 Case 3:04-cv-01271-B Document 92 Filed 11/17/05 Page 8 of 17 PageID 527
 

 Case 3:04-cv-01271-B Document 92 Filed 11/17/05 Page 9 of 17 PageID 528
 

 Case 3:04-cv-01271-B Document 92 Filed 11/17/05 Page 10 of 17 PageID 529
 

 Case 3:04-cv-01271-B Document 92 Filed 11/17/05 Page 11 of 17 PageID 530
 

 Case 3:04-cv-01271-B Document 92 Filed 11/17/05 Page 12 of 17 PageID 531
 

 Case 3:04-cv-01271-B Document 92 Filed 11/17/05 Page 13 of 17 PageID 532
 

 Case 3:04-cv-01271-B Document 92 Filed 11/17/05 Page 14 of 17 PageID 533
 

 Case 3:04-cv-01271-B Document 92 Filed 11/17/05 Page 15 of 17 PageID 534
 

 Case 3:04-cv-01271-B Document 92 Filed 11/17/05 Page 16 of 17 PageID 535
 

 Case 3:04-cv-01271-B Document 92 Filed 11/17/05 Page 17 of 17 PageID 536
Exhibit
32.1





CERTIFICATION
PURSUANT TO 18 U.S.C. SECTION 1350


AS
ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002








In
connection with the quarterly report of Trycera Financial (the “Company”)
on Form 10-Q for the quarter ended March 31, 2009, as filed with the
Securities and Exchange Commission (the “Report”), the undersigned principal
executive and financial officer of the Company, hereby certifies pursuant to 18
U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley
Act of 2002, that:








(1) the Report
fully complies with the requirements of Section 13(a) or 15(d) of the Securities
Exchange Act of 1934; and








(2) the
information contained in the Report fairly presents, in all material respects,
the financial condition and results of operations of the Company.






Company NameDate: May
      20, 2009
              By:
              /s/ Ray
      A. SmithRay
      Smith,President
      (Principal Executive Officer)
UNPUBLISHED UNITED STATES COURT OF APPEALS FOR THE FOURTH CIRCUIT No. 98-7722

FAUSTO CEPEDA, Plaintiff - Appellant, versus FEDERAL BUREAU OF INVESTIGATION; UNITED STATES OF AMERICA; JOHN R. HEALEY, Police Officer; PAUL V. KING, JR., Chief, Unit of Forfeiture and Seized Property Finance Division, Defendants - Appellees.Appeal from the United States District Court for the Eastern District of Virginia, at Richmond. James R. Spencer, District Judge. (CA-97-608-3) Submitted: March 11, 1999 Decided: March 18, 1999 Before WIDENER and LUTTIG, Circuit Judges, and PHILLIPS, Senior Circuit Judge. Affirmed by unpublished per curiam opinion. Fausto Cepeda, Appellant Pro Se. Debra Jean Prillaman, Assistant United States Attorney, Gurney Wingate Grant, II, OFFICE OF THE UNITED STATES ATTORNEY, Richmond, Virginia, for Appellees. Unpublished opinions are not binding precedent in this circuit. See Local Rule 36(c).2 PER CURIAM:Fausto Cepeda appeals the district court’s order denying relief in his action under Bivens v. Six Unknown Named Agents of Fed. Bureau of Narcotics , 403 U.S. 388 (1971). Cepeda has failed to adequately present any issues for appeal. Accordingly, we affirm. See 4th Cir. Local R. 34(b). We dispense with oral argument because the facts and legal contentions are adequately presented in the materials before the court and argument would not aid the decisional process.

AFFIRMED
Our efforts enable families in distress to 

keep their homes or avoid foreclosure.

more than

1.5M

loan workouts

since 2009

more than

1.2M

home

retention

solutions

approx.

345,500

foreclosure

alternatives

SDQ loans are those on which homeowners 

are 90+ days past due in making mortgage 

payments or that are in the foreclosure process. 

The share of single-family loans we hold or 

guarantee that are seriously delinquent (SDQ) 

has declined 15 consecutive quarters. 

(Substantially lower than

private market levels)

1Q

’10

1Q

’11

3Q

’10

3Q

’11

3Q

’12

1Q

’12

2Q

’10

2Q

’11

4Q

’10

4Q

’11

4Q

’12

2Q

’12

1Q

’13

2Q

’13

4Q

’13

1%

2%

3%

4%

5%

6%

5.47%

SDQ RATE

2.38%

3Q

’13

mortgage

refinancings

12.3

million

home

purchases

3.7 $4.1 Trillion million

rental units

2.2

million

This financing has enabled:

Since 2009,

we have provided approximately:

in liquidity to the mortgage market

1Q

’12

2Q

’12

3Q

’12

4Q

’12

4Q

’13

1Q

’13

2Q

’13

3Q

’13

$6.5B

net income

The country invested

$116.1 billion

in Fannie Mae 

from 2009 to 2012

Fannie Mae will 

have paid Treasury 

approximately

$121.1 billion

in dividends as 

of March 31, 2014

FANNIE MAE

Dividends do not offset prior draws.

STRONG PROFITABLE+$ GROWING

“NEW” BOOK

Loans acquired since 2009,

with stronger standards.

“LEGACY” BOOK

Loans acquired 

pre-2009

SINGLE-FAMILY

BOOK OF BUSINESS

23%

77%

Since Fannie Mae entered 

conservatorship, we have helped to 

stabilize America’s housing market 

and made significant progress in 

supporting the recovery and helping 

to build a sustainable housing finance 

system for the future. We are helping 

homeowners in distress and enabling 

families to buy, refinance, or rent a 

home.

Since 2009, we’ve improved our financial 

performance and we’re making a difference in people’s lives.

Fannie Mae is making progress.

For more information, see our 2013 Form 10-K Report,

filed with the SEC on February 21, 2014.

Data as of or through December 31, 2013, unless otherwise indicated.

Published February 21, 2014.

We reported our 8th consecutive

quarterly profit in Q4 2013. 

We enable families to buy, refinance, or rent a home.

We’re strengthening our book of business

and changing the industry.

We work with lenders 

to offer access to affordable 

mortgage credit.

We help homeowners 

who are facing hardship.

Our profits go back to

the American people.